US Exchange Filings

Exicure Plans Acquisition of NeuroQ Stake to Develop Parkinson’s Smart Glasses

Exicure is expanding beyond biotechnology into medical-device technology for Parkinson’s disease. The company has agreed with NeuroQ Biologics and Laonz to pursue an investment in NeuroQ, which now owns the X-CUE augmented-reality smart-glasses business.

X-CUE is designed to give visual cues to people with Parkinson’s who experience freezing of gait, episodes that can disrupt walking and everyday activities. The product has completed development of its latest version and is being prepared for clinical evaluation, but it has not yet cleared the clinical and regulatory steps needed for commercialization.

Key details

  • Exicure plans to acquire between 20% and 100% of NeuroQ. The proposed purchase would primarily involve issuing Exicure common shares in exchange for NeuroQ shares held by Laonz. The final stake, exchange ratio and other terms have not been set; they are to be negotiated in later written agreements and are subject to required approvals, including Nasdaq requirements.

  • Up to $500,000 in development funding is contemplated. After the proposed share acquisition is completed, Exicure intends to provide funding for X-CUE’s clinical evaluation, regulatory work, manufacturing preparation and commercialization efforts. The amount and funding itself remain conditional on approvals, available funds and definitive arrangements.

  • Laonz has already transferred the X-CUE business to NeuroQ. The transfer includes the related intellectual property, technology, assets and business rights.

  • NeuroQ is to lead the program. It will oversee further development, clinical evaluation, regulatory approval and commercialization, with strategic support from Exicure.

  • Clinical evaluation is planned, not completed. Exicure says the latest, third-revised version of X-CUE has finished product development and is ready for planned clinical trials. The anticipated evaluation period is about six months. Commercialization remains dependent on successful clinical evaluation and regulatory approvals.

  • Exicure is broadening its strategic focus. The company says its portfolio also includes a clinical-stage program targeting stem-cell mobilization for multiple myeloma, sickle cell disease, and cell- and gene-therapy applications.

Plain-English implications

The agreement sets out a potential route for Exicure to gain a substantial ownership stake in a medical-device business, with the consideration expected to be primarily Exicure shares. But the ownership percentage, share terms and funding are not final, and the proposed acquisition has not been completed. X-CUE’s development history and stated readiness for clinical evaluation do not establish that it will prove effective or reach the market.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.